Pharmaceuticals
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III c...
2024-11-12 19:30
1348
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
* After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. * The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. * The safety and tolerability of G...
2024-11-12 19:00
1154
Tsingke Successfully Showcases Innovations at BIO-Europe 2024
BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke
2024-11-12 17:07
923
World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)
- Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as Well as Their Manufacturing Methods - TOKYO, Nov. 12, 2024 /PRNewswire/ -- Scarecrow Incorporated, based in Tokyo's Shibuya Ward, is pleased to announce that it has acquired the worl...
2024-11-12 14:00
1185
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...
2024-11-11 21:45
1475
Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthier future
Members of the media are invited to register here
2024-11-11 20:56
1763
Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes
* Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day * 1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles[1] * People with dia...
2024-11-11 20:47
1244
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...
2024-11-11 20:30
1005
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
* Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0....
2024-11-11 19:36
1168
TB Alliance Joins Indonesia's High-Level Meeting on TB
Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies...
2024-11-11 10:30
1301
Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024
SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune check...
2024-11-11 10:04
1346
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
2024-11-11 08:07
1230
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity ofSaudi Arabia's prominent family business group...
2024-11-09 00:35
4086
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
2330
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
1422
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
1178
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-11-08 17:45
1090
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...
2024-11-08 11:27
1685
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN1...
2024-11-08 10:40
1324
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held inHouston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, ...
2024-11-08 08:20
1324
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 283 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8674
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5354
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4730
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4681